Tue. Sep 27th, 2022

As per DelveInsight’s assessment, globally, about 18+ key pharma and biotech companies are working in the Fabry Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Fabry Disease Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Fabry Disease Therapeutics Market. 

The report provides a detailed description of the emerging drugs, including their type, stage, Mechanism of Action (MoA), Route of Administration (RoA), molecule type, inactive pipeline products, and NDA approvals. 

The report also covers in-depth commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed phase. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Fabry Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies in the Fabry Disease Market.
  • It accesses the different therapeutic candidates segmented into early-stage (phase I), mid-stage (phase II), and late-stage (phase III) development. 
  • It assesses the targeted drug therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Fabry Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. 

Key Developments in the Fabry Disease Therapeutics Market

On September 07, 2022, AceLink Therapeutics, Inc. (AceLink) announced it had received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for AL01211 as a treatment for Fabry disease. AL01211 is a proprietary GCS inhibitor with excellent potency (single-digit nanomolar IC50) and has several other favorable drug properties.


 

On August 30, 2022, Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, for the treatment of Fabry disease.

 

Learn How the Ongoing Clinical & Commercial Activities will Affect the Fabry Disease Therapeutic Segment:

https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight

Fabry Disease Therapeutics Analysis

There are approx. 18+ key companies which are developing therapies for Fabry Disease. Currently, Protalix Biotherapeutics has its Fabry Disease drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Fabry Disease Therapeutics Market include:

  • Idorsia Pharmaceuticals
  • Protalix
  • Sanofi Genzyme
  • Sangamo Therapeutics
  • 4D Molecular Therapeutics
  • Resverlogix Corp
  • AVROBIO
  • Freeline Therapeutics
  • Ozmosis Research Inc.
  • CellGenTech, Inc.
  • uniQure
  • Codexis
  • Canbridge
  • Eleva GmbH
  • MP6 therapeutics
  • Amicus therapeutics
  • Sigilon Therapeutics
  • Protalix Biotherapeutics

And many others

Fabry Disease Emerging Drugs Covered in the Report Include: 

  • Pegunigalsidase Alfa: Protalix Biotherapeutics
  • Venglustat: Sanofi
  • 4D 310: 4D Molecular Therapeutics

And many More

DelveInsight’s Report covers around 18+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight

Table of Content

  1. Report Introduction
  2. Executive Summary
  3. Fabry Disease Current Treatment Patterns
  4. Fabry Disease – DelveInsight’s Analytical Perspective
  5. Therapeutic Assessment
  6. Fabry Disease Late Stage Products (Phase-III)
  7. Fabry Disease Mid-Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Fabry Disease Discontinued Products
  13. Fabry Disease Product Profiles
  14. Fabry Disease Key Companies
  15. Fabry Disease Key Products
  16. Dormant and Discontinued Products
  17. Fabry Disease Unmet Needs
  18. Fabry Disease Future Perspectives
  19. Fabry Disease Analyst Review  
  20. Appendix
  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Contact Info:
Anuj Rawat
Email: [email protected]
https://www.delveinsight.com/
Request for Sample Copy of the Report at:

Other Trending Healthcare Reports By DelveInsight

Fabry Disease Market Insight

“Fabry Disease Market Insights, Epidemiology, and Market Forecast” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Fabry Disease market size and shares analysis in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Fabry Disease Epidemiology Forecast

“Fabry Disease Epidemiology Forecast” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology of Fabry Disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

By krehani

Leave a Reply

Your email address will not be published. Required fields are marked *